A Phase 1 interventional study of BMS-986419 and BMS-986419 Matching Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986419
Drug: BMS-986419 Matching Placebo
Drug: BMS-986419 · Drug: BMS-986419 Matching Placebo · Drug: Moxifloxacin Matching Placebo
Drug: BMS-986419 Matching Placebo · Drug: Moxifloxacin · Drug: Moxifloxacin Matching Placebo
Drug: BMS-986419 Matching Placebo · Drug: Moxifloxacin · Drug: Moxifloxacin Matching Placebo
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Part 1: Number of Participants with Non-serious Adverse Events (NSAEs)
Time frame: Up to approximately Day 42
Part 1: Number of Participants with Serious Adverse Events (SAEs)
Time frame: Up to approximately Day 42
Part 1: Number of Participants with AEs Leading to Discontinuation
Time frame: Up to approximately Day 42
Part 1: Number of Participants With AEs of Special Interest (AESI)
Time frame: Up to approximately Day 42
Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities
Vital sign parameters include temperature, systolic blood pressure (BP), diastolic BP, respiratory rate, and heart rate (HR) assessment.
Time frame: Up to approximately Day 21
Part 1: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities
Time frame: Up to approximately Day 21
Part 1: Number of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities
Time frame: Up to approximately Day 21
Part 1: Number of Participants With Clinically Significant Columbia-Suicide Severity Rating Scale (C-SSRS) Abnormalities
Time frame: Up to approximately Day 21
Part 1: Number of Participants With Clinically Significant Neurological Examination Abnormalities
Time frame: Up to approximately Day 21
Part 1: Number of Participants With Physical Examination Abnormalities
Time frame: Up to approximately Day 21
Part 2: ΔQTc: Change From Baseline in Plasma Concentration of BMS-986419 on Cardiac Repolarization Expressed by QT interval (QTc)
ΔQTc is performed by primary correction.
Time frame: Up to approximately Day 15
Part 2: ΔΔQTc: Placebo-corrected Change From Baseline QTc Plasma Concentration of BMS-986419 on Cardiac Repolarization Expressed by QTc
Time frame: Up to approximately Day 15
Part 1: Maximum Observed Plasma Concentration (Cmax) of BMS-986419
Time frame: Up to approximately Day 21
Part 1: Time of Maximum Plasma Observed Concentration (Tmax) of BMS-986419
Time frame: Up to approximately Day 21
Part 1: Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU)) of BMS-986419
Time frame: Up to approximately Day 21
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC [0-T]) of BMS-986419
Time frame: Up to approximately Day 21
Part 1: Terminal Phase Elimination Half-life (T-Half) of BMS-986419
Time frame: Up to approximately Day 21
Part 1: Accumulation Index; Ratio of Cmax at Steady-state to Cmax After the First Dose (AI_Cmax) of BMS-986419
Time frame: Up to approximately Day 21
Part 1: Accumulation Index; Ratio of AUC(TAU) at Steady-state to AUC(TAU) After the First Dose [AI_AUC(TAU)] of BMS-986419
Time frame: Up to approximately Day 21
Part 1: Apparent Total Body Clearance (CLT/F) of BMS-986419
Time frame: Up to approximately Day 21
Part 1: Apparent Volume of Distribution of Terminal Phase (Vz/F) of BMS-986419
Time frame: Up to approximately Day 21
Part 1: Trough Concentration of BMS-986419
Time frame: Up to approximately Day 21
Part 2: ΔQTc of BMS-986419 Using Change From Baseline of Heart Rate (HR)(ΔHR) Correction
Time frame: Up to approximately Day 15
Part 2: ΔQTc of BMS-986419 Using Change From Baseline of Pulse Rate (PR)(ΔPR) Correction
Time frame: Up to approximately Day 15
Part 2: ΔQTc of BMS-986419 Using Change From Baseline of Respiratory Rate (RR) Interval Correction
Time frame: Up to approximately Day 15
Part 2: Change From Baseline of BMS-986419 in Quality Rating System (QRS) Interval (ΔQRS)
Time frame: Up to approximately Day 15
Part 2: Number of Participants With Treatment-emergent Values of Fridericia's Corrected QT interval (QTcF) for BMS-986419
Participants with increase in absolute treatment-emergent QTc values \>450 and ≤480 milliseconds (msec), \>480 and ≤500 msec, or \>500 msec, and changes from pre-dose baseline of \>30 and ≤ 60 msec, or \>60 msec will be measured.
Time frame: Up to approximately Day 15
Part 2: Number of Timepoints With Change in Absolute Treatment-emergent QTcF Values for BMS-986419
Number of timepoints with increase in absolute treatment-emergent QTc values \>450 and ≤480 milliseconds (msec), \>480 and ≤500 msec, or \>500 msec, and changes from pre-dose baseline of \>30 and ≤ 60 msec, or \>60 msec will be measured.
Time frame: Up to approximately Day 15
Part 2: Number of Participants With Treatment-emergent Values of Individualized Heart Rate-corrected Interval/Optimized HR-corrected QT Interval (QTcS/QTcI) for BMS-986419
Time frame: Up to approximately Day 15
Part 2: Number of Participants With Treatment-emergent Values of HR for BMS-986419
Participants with decrease in HR from pre-dose baseline \>25% to a HR \<50 beats per minute (bpm); and increase in HR from pre-dose baseline \>25% to a HR \>100 bpm will be determined.
Time frame: Up to approximately Day 15
Part 2: Number of Timepoints With Change in Absolute Treatment-emergent HR Values for BMS-986419
Number of timepoints with decrease in HR from pre-dose baseline \>25% to a HR \<50 beats per minute (bpm); and increase in HR from pre-dose baseline \>25% to a HR \>100 bpm will be determined.
Time frame: Up to approximately Day 15
Part 2: Number of Participants With Treatment-emergent Values of PR for BMS-986419
Participants with increase in PR from pre-dose baseline \>25% to a PR\>200 msec will be determined.
Time frame: Up to approximately Day 15
Part 2: Number of Timepoints With Increase in Absolute Treatment-emergent PR Values for BMS-986419
Number of timepoints with increase in PR from pre-dose baseline \>25% to a PR\>200 msec will be determined.
Time frame: Up to approximately Day 15
Part 2: Number of Participants With Treatment-emergent Values of QRS for BMS-986419
Participants with increase in QRS from pre-dose baseline \>25% to a QRS \>120 msec will be determined.
Time frame: Up to approximately Day 15
Part 2: Number of Timepoints With Increase in Absolute Treatment-emergent QRS Values for BMS-986419
Number of timepoints with increase in QRS from pre-dose baseline \>25% to a QRS \>120 msec will be determined.
Time frame: Up to approximately Day 15
Part 2: Number of Participants With New Onset ECG Morphology Findings
"New" means an ECG finding that is not present on any baseline ECG \[that is, any ECG recorded prior to receipt of the first dose of study BMS-986419\] and becomes present on at least 1 on-treatment ECG during that treatment period).
Time frame: Up to approximately Day 15
Part 2: ΔQTc: Change From Baseline in Plasma Concentration of Moxifloxacin on Cardiac Repolarization Expressed by QT interval (QTc)
ΔQTc is performed by primary correction.
Time frame: Up to approximately Day 15
Part 2: ΔΔQTc: Placebo-corrected Change From Baseline QTc Plasma Concentration of Moxifloxacin on Cardiac Repolarization Expressed by QTc
Time frame: Up to approximately Day 15
Part 2: Number of Participants with NSAEs
Time frame: Up to approximately Day 36
Part 2: Number of Participants with SAEs
Time frame: Up to approximately Day 36
Part 2: Number of Participants with AEs Leading to Discontinuation
Time frame: Up to approximately Day 36
Part 2: Number of Participants With AESI
Time frame: Up to approximately Day 36
Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities
Vital sign parameters include temperature, systolic BP, diastolic BP, respiratory rate, and HR assessment.
Time frame: Up to approximately Day 15
Part 2: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities
Time frame: Up to approximately Day 14
Part 2: Number of Participants With Clinically Significant 12-Lead ECG Abnormalities
Time frame: Up to approximately Day 15
Part 2: Number of Participants With Clinically Significant C-SSRS Abnormalities
Time frame: Up to approximately Day 15
Part 2: Number of Participants With Clinically Significant Neurological Examination Abnormalities
Time frame: Up to approximately Day 15
Part 2: Number of Participants With Physical Examination Abnormalities
Time frame: Up to approximately Day 15
Part 2: Cmax of BMS-986419
Time frame: Up to approximately Day 15
Part 2: Tmax of BMS-986419
Time frame: Up to approximately Day 15
Part 2: AUC(0-T) of BMS-986419
Time frame: Up to approximately Day 15
Part 2: AUC(TAU) of BMS-986419
Time frame: Up to approximately Day 15
Part 2: T-Half of BMS-986419
Time frame: Up to approximately Day 15
Part 2: AI_Cmax of BMS-986419
Time frame: Up to approximately Day 15
Part 2: AI_AUC(TAU) of BMS-986419
Time frame: Up to approximately Day 15
Part 2: Trough Concentration of BMS-986419
Time frame: Up to approximately Day 15
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Ran from Feb 2025 to primary completion in Oct 2025, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Comtifator · Moxifloxacin